• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

RANK/RANKL在前列腺癌中的表达。

RANK/RANKL expression in prostate cancer.

作者信息

Ohtaka Mari, Kawahara Takashi, Mochizuki Taku, Takamoto Daiji, Hattori Yusuke, Teranishi Jun-Ichi, Miyoshi Yasuhide, Yumura Yasushi, Hasumi Hisashi, Yokomizo Yumiko, Hayashi Narihiko, Kondo Keiichi, Yao Masahiro, Miyamoto Hiroshi, Uemura Hiroji

机构信息

Departments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan.

Departments of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Japan; Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.

出版信息

Int J Surg Case Rep. 2017;30:106-107. doi: 10.1016/j.ijscr.2016.11.042. Epub 2016 Nov 29.

DOI:10.1016/j.ijscr.2016.11.042
PMID:28012322
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5192013/
Abstract

• Expression of and genes in prostate cancer is higher than non-neoplastic prostate. • expression is not related to pathological features. • There is no significant correlation of / expression with biochemical recurrence after radical prostatectomy.

摘要

• 与基因在前列腺癌中的表达高于非肿瘤性前列腺组织。

• 表达与病理特征无关。

• 前列腺癌根治术后，/表达与生化复发无显著相关性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cf9/5192013/66a49d23218c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cf9/5192013/66a49d23218c/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8cf9/5192013/66a49d23218c/gr1.jpg

相似文献

1
RANK/RANKL expression in prostate cancer.RANK/RANKL在前列腺癌中的表达。
Int J Surg Case Rep. 2017;30:106-107. doi: 10.1016/j.ijscr.2016.11.042. Epub 2016 Nov 29.
2
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.RANKL/RANK/OPG在原发性和转移性人类前列腺癌中的表达作为疾病分期和功能调节的标志物
Cancer. 2006 Jul 15;107(2):289-98. doi: 10.1002/cncr.21978.
3
Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.OPG/RANK/RANKL 轴在前列腺癌侵袭和骨转移中的潜在作用。
Oncol Rep. 2014 Dec;32(6):2605-11. doi: 10.3892/or.2014.3511. Epub 2014 Sep 23.
4
RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.核因子κB受体活化因子配体（RANKL）直接作用于表达核因子κB受体活化因子（RANK）的前列腺肿瘤细胞，并介导肿瘤转移基因的迁移和表达。
Prostate. 2008 Jan 1;68(1):92-104. doi: 10.1002/pros.20678.
5
DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.DU145人前列腺癌细胞表达核因子κB受体激活剂：前列腺癌骨转移过程中的新见解。
Bone. 2007 Apr;40(4):981-90. doi: 10.1016/j.bone.2006.11.006. Epub 2006 Dec 28.
6
Influence of simultaneous targeting of the bone morphogenetic protein pathway and RANK/RANKL axis in osteolytic prostate cancer lesion in bone.骨形态发生蛋白通路与RANK/RANKL轴同时靶向对骨溶骨性前列腺癌病灶的影响。
Bone. 2009 Jan;44(1):160-7. doi: 10.1016/j.bone.2008.09.009. Epub 2008 Sep 26.
7
Osteoprotegerin and rank ligand expression in prostate cancer.骨保护素与前列腺癌中核因子κB受体活化因子配体的表达
Urology. 2001 Apr;57(4):611-6. doi: 10.1016/s0090-4295(00)01122-5.
8
Inhibition of the RANK/RANKL signaling with osteoprotegerin prevents castration-induced acceleration of bone metastasis in castration-insensitive prostate cancer.骨保护素通过抑制 RANK/RANKL 信号通路可预防去势抵抗性前列腺癌骨转移的加速。
Cancer Lett. 2017 Jul 1;397:103-110. doi: 10.1016/j.canlet.2017.03.034. Epub 2017 Mar 31.
9
RANK/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment.抑制 RANK/RANKL 信号通路可能会提高检查点抑制剂在癌症治疗中的疗效。
Crit Rev Oncol Hematol. 2019 Jan;133:85-91. doi: 10.1016/j.critrevonc.2018.10.011. Epub 2018 Nov 3.
10
Rankl expression predicts poor prognosis in gastric cancer patients: results from a retrospective and single-center analysis.RANKL表达预示胃癌患者预后不良：一项回顾性单中心分析结果
Braz J Med Biol Res. 2018 Jan 11;51(3):e6265. doi: 10.1590/1414-431X20176265.

引用本文的文献

1
Elevated tissue expression of RANKL and RANK is associated with poorer survival rates in pancreatic cancer patients.组织中 RANKL 和 RANK 的高表达与胰腺癌患者生存率降低相关。
Histol Histopathol. 2024 Sep;39(9):1133-1140. doi: 10.14670/HH-18-700. Epub 2023 Dec 29.
2
The RANK-RANKL-OPG System: A Multifaceted Regulator of Homeostasis, Immunity, and Cancer.RANK-RANKL-OPG 系统：稳态、免疫和癌症的多效调节剂。
Medicina (Kaunas). 2023 Sep 30;59(10):1752. doi: 10.3390/medicina59101752.
3
Dual roles of cellular communication network factor 6 (CCN6) in the invasion and metastasis of oral cancer cells to bone via binding to BMP2 and RANKL.

本文引用的文献

1
The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases.RANK基因单核苷酸多态性位点rs34945627在伴有骨转移的乳腺癌患者中的预后作用。
Oncotarget. 2016 Jul 5;7(27):41380-41389. doi: 10.18632/oncotarget.9356.
2
The role of NFATc1 in prostate cancer progression: cyclosporine A and tacrolimus inhibit cell proliferation, migration, and invasion.NFATc1在前列腺癌进展中的作用：环孢素A和他克莫司抑制细胞增殖、迁移和侵袭。
Prostate. 2015 May;75(6):573-84. doi: 10.1002/pros.22937. Epub 2015 Jan 28.
3
Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study.
细胞通讯网络因子 6（CCN6）通过与 BMP2 和 RANKL 结合在口腔癌细胞骨侵袭和转移中的双重作用。
Carcinogenesis. 2023 Dec 2;44(8-9):695-707. doi: 10.1093/carcin/bgad057.
4
Prostate adenocarcinoma with osteolytic metastases: Case report and review of the literature.前列腺腺癌伴溶骨性转移：病例报告及文献复习
Radiol Case Rep. 2021 Sep 15;16(11):3565-3568. doi: 10.1016/j.radcr.2021.08.056. eCollection 2021 Nov.
5
RANKL immunisation inhibits prostate cancer metastasis by modulating EMT through a RANKL-dependent pathway.RANKL 免疫抑制通过 RANKL 依赖性途径调节 EMT 抑制前列腺癌转移。
Sci Rep. 2021 Jun 9;11(1):12186. doi: 10.1038/s41598-021-91721-2.
地舒单抗对比唑来膦酸治疗去势抵抗性前列腺癌骨转移患者的随机、双盲研究。
Lancet. 2011 Mar 5;377(9768):813-22. doi: 10.1016/S0140-6736(10)62344-6. Epub 2011 Feb 25.
4
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling.肿瘤浸润调节性 T 细胞通过 RANKL-RANK 信号促进乳腺癌转移。
Nature. 2011 Feb 24;470(7335):548-53. doi: 10.1038/nature09707. Epub 2011 Feb 16.
5
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis.RANK 配体介导孕激素诱导的乳腺上皮细胞增殖和癌变。
Nature. 2010 Nov 4;468(7320):103-7. doi: 10.1038/nature09495. Epub 2010 Sep 29.
6
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer.核因子κB 受体激活配体（RANKL）可促进孕激素诱导的乳腺癌发生。
Nature. 2010 Nov 4;468(7320):98-102. doi: 10.1038/nature09387. Epub 2010 Sep 29.
7
Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.RANKL表达增加与肾细胞癌的肿瘤迁移和转移有关。
J Pathol. 2009 Aug;218(4):530-9. doi: 10.1002/path.2567.
8
Receptor activator of NF-kappaB Ligand (RANKL) expression is associated with epithelial to mesenchymal transition in human prostate cancer cells.核因子κB受体激活剂配体（RANKL）的表达与人前列腺癌细胞的上皮-间质转化相关。
Cell Res. 2008 Aug;18(8):858-70. doi: 10.1038/cr.2008.84.
9
Expression of RANKL/RANK/OPG in primary and metastatic human prostate cancer as markers of disease stage and functional regulation.RANKL/RANK/OPG在原发性和转移性人类前列腺癌中的表达作为疾病分期和功能调节的标志物
Cancer. 2006 Jul 15;107(2):289-98. doi: 10.1002/cncr.21978.
10
Regulation of cancer cell migration and bone metastasis by RANKL.RANKL对癌细胞迁移和骨转移的调控
Nature. 2006 Mar 30;440(7084):692-6. doi: 10.1038/nature04524.